Vladimir Novitsky, M.D., Ph.D., is a Principal Research Scientist in the Department of Immunology and Infectious Diseases at the Harvard School of Public Health. Dr. Novitsky has made a number of significant contributions to the virological and immunological study of HIV-1 infection. The main focus of Dr. Novitsky’s research is molecular analysis of the HIV-1 subtype C epidemic, genotypic and phenotypic characterization of the HIV-1 subtype C genome, and potential associations between virological and immunological parameters in early and acute HIV-1 subtype C infection. He contributed significantly to the design, planning, capacity building, and supervision of the Botswana–Harvard AIDS Institute Laboratory in Botswana. Dr. Novitsky is the Principal Investigator of the ongoing Acute HIV-1 Subtype C Infection study in Botswana (R01: Markers of Viral Set Point in Primary HIV-1C Infection). He is also a Co-Investigator in two other ongoing studies in Botswana. He was a member of the HVTN protocol development team for a “Phase I Dose-Escalation Clinical Trial to Evaluate the Safety and Immunogenicity of the EP HIV-1090 DNA Vaccine in Healthy, HIV-1-Uninfected Adult Participants.” Dr. Novitsky is a reviewer for the Bill & Melinda Gates Foundation, Vaccine, AIDS Research and Human Retroviruses, Journal of Infectious Diseases, and Journal of Medical Virology. Dr. Novitsky has authored 43 peer-reviewed publications in Science, New England Journal of Medicine, Journal of Virology, Journal of Immunology, Virology, AIDS, Journal of Infectious Diseases, Clinical Infectious Diseases, AIDS Research and Human Retroviruses, Human Immunology, PLoS One, JAMA, Antimicrobial Agents and Chemotherapy, AIDS Care, Antiviral Chemistry & Chemotherapy, Clinical and Diagnostic Laboratory Immunology, Vaccine, Journal of Immunological Methods, Journal of Computational Biology, and Virological Methods, as well as two book chapters.